All Articles

Invasive breast cancer will be diagnosed in an estimated 300,000 American women in 2023. Early screening and targeted treatment have improved overall survival since the late 1980s, but breast cancer remains the second most common cause of cancer death in women, occurring in 1 in 39 women.

This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.

This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.

This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.